Promising combo for brain metastases halted early – only 5 patients enrolled
NCT ID NCT04791384
First seen Mar 31, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs, abemaciclib and elacestrant, in women with a certain type of breast cancer (HR+/Her2-) that had spread to the brain. The goal was to see if the drugs were safe and could shrink or control brain tumors. Only 5 patients were enrolled before the study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Northwest
Spokane Valley, Washington, 99216, United States
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.